CIK 0001710072 · Large accelerated filer
Edgewise Therapeutics, Inc.
Sign in to watch- Ticker
- EWTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821725586
- Phone
- 720-262-7002
- Business address
- 1715 38TH ST, BOULDER, CO, 80301
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $201,787
- in 1 filing
Net −$201,787. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-01 | MOORE JOHN R General Counsel | Option exercise | +5,208 | 8,462 | ||
| 2023-05-01 | MOORE JOHN R General Counsel | Option exercise · Restricted Stock Units | −5,208 | 10,417 | ||
| 2023-05-01 | Carruthers R Michael Chief Financial Officer | Option exercise | +5,208 | 17,462 | ||
| 2023-05-01 | Carruthers R Michael Chief Financial Officer | Option exercise · Restricted Stock Units | −5,208 | 10,417 | ||
| 2023-05-01 | Russell Alan J Chief Scientific Officer | Option exercise | +5,208 | 177,793 | ||
| 2023-05-01 | Russell Alan J Chief Scientific Officer | Option exercise · Restricted Stock Units | −5,208 | 10,417 | ||
| 2023-05-01 | Donovan Joanne M. CMO | Option exercise | +10,416 | 13,214 | ||
| 2023-05-01 | Donovan Joanne M. CMO | Option exercise · Restricted Stock Units | −10,416 | 20,834 | ||
| 2023-05-01 | KOCH KEVIN President and CEO | Option exercise | +10,416 | 10,416 | ||
| 2023-05-01 | KOCH KEVIN President and CEO | Option exercise · Restricted Stock Units | −10,416 | 20,834 | ||
| 2023-03-03 | Fox Jonathan C Director | Grant or award · Stock Option (Right to Buy) | +43,731 | 43,731 | ||
| 2022-12-30 | Semigran Marc Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2022-10-03 | MOORE JOHN R General Counsel | Option exercise | +4,730 | $1.93 | $9K | 7,730 |
| 2022-10-03 | MOORE JOHN R General Counsel | Sale | −4,730 | $9.76 | $46K | 3,000 |
| 2022-10-03 | MOORE JOHN R General Counsel | Option exercise · Stock Option (Right to Buy) | −4,730 | 122,997 | ||
| 2022-09-16 | Thompson Peter A. Director | Purchase | +484,496 | $10.32 | $5.0M | 13,981,952 |
| 2022-09-16 | ORBIMED ADVISORS LLC Director | Purchase | +484,496 | $10.32 | $5.0M | 13,981,952 |
| 2022-09-14 | Novo Holdings A/S 10% owner | Purchase | +484,496 | $10.32 | $5.0M | 6,071,703 |
| 2022-09-06 | MOORE JOHN R General Counsel | Option exercise | +4,730 | $1.93 | $9K | 7,730 |
| 2022-09-06 | MOORE JOHN R General Counsel | Sale | −2,379 | $10.83 | $26K | 5,351 |
Page 17 of 26 · 509 trades